EFTR - eFFECTOR Therapeutics GAAP EPS of -$0.23 revenue of $0.87M November, 07 2022 05:06 PM eFFECTOR Therapeutics Inc. eFFECTOR Therapeutics press release ( NASDAQ: EFTR ): Q3 GAAP EPS of -$0.23. Revenue of $0.87M (+102.3% Y/Y). For further details see: eFFECTOR Therapeutics GAAP EPS of -$0.23, revenue of $0.87M